Mineralys Therapeutics, Inc.
NASDAQ:MLYSBiotechnology
+$0.37 today
- Market cap
- $1.25B
- Beta
- 0.56
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$1.83
Volume 1.17M
Average 1.48M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
Intrinsic Alpha fair value
Locked
Current Price
$14.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Travere Therapeutics, Inc. NASDAQ:TVTX | $4.86B | $50.65 | Overvalued | -235.0 | +39.07% |
Vera Therapeutics, Inc. NASDAQ:VERA | $2.03B | $28.10 | Not rated | -6.8 | -4.02% |
Maze Therapeutics, Inc. NASDAQ:MAZE | $1.88B | $34.33 | Not rated | -11.0 | -8.83% |
DiaMedica Therapeutics Inc. NASDAQ:DMAC | $474.01M | $8.79 | Not rated | -8.8 | +11.08% |
Orchestra BioMed Holdings, Inc. NASDAQ:OBIO | $435.76M | $7.25 | Not rated | -2.8 | +58.01% |
Unicycive Therapeutics, Inc. NASDAQ:UNCY | $97.25M | $3.55 | Not rated | -40.8 | -33.02% |
Continue the stock analysis
Jump to another research area for this company.